BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2021

BIOQUAL, Inc. (OTC Pink: BIOQ) reported its unaudited second quarter results for fiscal year 2021.

(Low)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

earnings

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/22/2021 - 09:41 AM

BIOQUAL, Inc. (OTC Pink: BIOQ) (www.bioqual.com):


	Six Months Ended November 30,				Three Months Ended November 30,
		2020		2019		2020		2019
Revenue	$	28,486,183	$	21,290,838	$	13,565,708	$	11,222,962
Income Before Income Tax	$	4,562,602	$	3,132,524	$	2,065,614	$	1,258,041
Net Income	$	3,228,002	$	2,216,324	$	1,461,414	$	891,841
Basic Earnings per Share
of Common Stock	$	3.61	$	2.48	$	1.63	$	1.00

Diluted Earnings per Share
of Common Stock	$	3.61	$	2.48	$	1.63	$	1.00

Weighted Average
Number of Shares Outstanding
For Basic Earnings Per Share		893,694		893,416		893,976		893,416

Weighted Average
Number of Shares Outstanding
For Diluted Earnings Per Share		893,694		893,838		893,976		893,838

For more detail related to the fiscal year 2021 unaudited second quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.